M ajor histocompatibility complex class II (MHCII)
glycoproteins are known to play a deciding role in the selection of helper and regulatory CD4 + T lymphocytes (1) . The contribution of MHCII molecules plus self-peptide (pMHCII) complexes to CD4 + T cell differentiation/activation has been well documented (2) . Likewise, pMHCII complexes are involved in the thymic differentiation of naturally occurring CD4 + CD25 + Foxp3 + regulatory T cells (Tregs) (3, 4) . In addition to their prominent role in CD4 + cell differentiation, MHCII molecules have been implicated in the regulation of immune responses, a function that was the cornerstone of their discovery (5) but remains poorly understood. It is widely accepted that the avidity of MHCII heterodimers for foreign peptides and the density of resulting pMHCII complexes on APCs modulate CD4 + T cell activation (6) (7) (8) (9) . However, there is mounting evidence that the regulatory role of MHCII molecules is not confined to their ability to bind or not bind peptides. Indeed, inverse correlations between peptide avidity for MHCII and the magnitude of T cell responses were reported (10, 11) . Other instances in clinical and experimental transplantation showed that matching for MHCII loci between graft donors and hosts downmodulated T cell responses to allografts and improved graft survival (12, 13) . These data indicated that immune regulation via MHCII was mostly independent of the avidity of MHCII for graft-derived peptides and that transplantation models may be especially suited to decipher the regulatory function of MHCII genes.
To assess whether MHCII regulatory control on T cell responses was mediated by MHCII genes and not by other genes mapping in the MHCII locus, pilot gene-therapy experiments were carried out in a preclinical transplantation model (14) . The results demonstrated that transfer of donor MHCII genes into bone marrow cells (BMCs) of future graft recipients induced immune tolerance to kidney transplants that were fully allogeneic to the hosts (15, 16) . They also suggested that the MHCII-induced tolerance was regulatory, because T cell responses to all donor major and minor Ags were repressed. However, the mechanism of downregulation of immune responses by MHCII remains to be demonstrated.
The present study investigated the mechanism of MHCII control over T cell responses to allogeneic cardiac transplants in mice. We demonstrated that transfer of a single donor MHCII gene in recipient BMCs resulted in donor-specific tolerance and long-term survival of fully allogeneic transplants expressing this donor MHCII gene. MHCII-induced tolerance was selectively carried by Tregs and involved cytosolic forms of transferred MHCII molecules expressed in/ on APCs. Furthermore, MHCII gene transfer prevented the onset of chronic rejection characterized by cardiac allograft vasculopathy (CAV), the chief cause of graft loss in clinical transplantation (17) . These findings provide a novel mechanism to account for the regulatory role of MHCII genes, by showing that MHCII has the unique property of inducing Tregs that ultimately suppress the T cell alloresponses involved in acute and chronic allograft rejection.
Materials and Methods

Animals
Six-to eight-week-old female BALB/c (H-2   d   ), CBA (H-2   k   ) , and C57BL/6 (B6: H-2 b ) mice were purchased from The Jackson Laboratory (Bar Harbor, ME). They were maintained in our pathogen-free facility at the Massachusetts General Hospital animal facility and treated according to institutional guidelines.
Cells
Dendritic cells (DCs) were derived from retrovirally transduced BMCs from CBA/J mice. Nonadherent transduced BMCs (2 3 10 6 cells/ml) were plated in 4 ml RPMI 1640 medium containing 500 U/ml murine rGM-CSF (BioSource International, Camarillo, CA) in six-well plates. Every other day, one-half of the medium was refreshed. On day 7, 50 U/ml recombinant murine IL-4 (BioSource International) was added in addition to GM-CSF to derive mature DCs (mDCs). Cells were harvested for analyses 4 d later. CD11c
+ cells for quantitative RT-PCR (qRT-PCR) analysis were purified over magnetic columns after staining with biotin-conjugated anti-CD11c mAb (clone HL3, BD Pharmingen, San Diego, CA), followed by anti-Biotin MicroBeads (Miltenyi Biotec, Auburn, CA). CD4 + T cell subset enrichment (.90%) was performed on splenocytes using the Regulatory T Cell Isolation Kit (Miltenyi Biotec).
Retroviral vectors
Constructs contain the LN vector backbone (18) , modified with a myeloproliferative sarcoma virus enhancer in the 39 long terminal repeat (19) . The IAb.RV construct derived from the plasmid pPBM19 containing the porcine MHCII DRA and DRB cDNA, spaced by the internal ribosome entry site (IRES), from the 59 untranslated IgH-binding protein (19) . The following modifications were made: the EMC-neo(r)-SV40 ori fragment was removed by digestion with BglII and ClaI, and the SLA-DRB and SLA-DRA sequences were replaced, respectively, with murine sequences for I-Ab b (bases 216-822, 900-bp EcoRI 3 HincII fragment from plasmid pcEXV-Ab To construct the IAb-GFP.RV plasmid, the stop codon of the I-Aa b cDNA in IAb.RV was mutated (in bold, underlined), and a 39 AgeI restriction site was added using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) and primers 59-CCCAGGGCCTTTAAGAGTCACACCGGTG-AAAGGAAGGCG-39 and59-CGCCTTCCTTTCACCGGTGTGACTCTT-AAAGGCCCTGGG-39. The enhanced GFP (eGFP) cDNA, isolated from plasmid pEGFP-1 (BD Clontech, Palo Alto, CA), was cloned in-frame with the I-Aa b mutated cDNA. The GFP.RV construct (pPBM25-1) was previously reported, and virus-containing supernatants were prepared as described (20) .
Retroviral transduction
CBA/J mice were treated with fluorouracil (150 mg/kg, i.v.), and BMCs were harvested 7 d later for transduction. Transduction was performed as described (20) , with some modifications: recombinant mouse stem cell factor was from BioSource International, and retronectin-coated wells were preloaded with retrovirus for 3 h at 37˚C. L cell fibroblasts were transduced using supernatants diluted 1:5 in complete DMEM + 16 mg/ml polybrene for 2 h at 37˚C.
Conditioning protocols for bone marrow and heart transplantation
Transplantation of transduced BMCs (1 3 10 6 cells/mouse, i.v.) was performed in CBA mice receiving two injections of anti-CD4 (GK1.5), anti-CD8 (2.43) Abs (1 mg each/mouse, i.p.) at days 23 and 21 relative to bone marrow transplantation. Animals also received 10 mg/kg Busulfex at days 2 4, 23, 22, and 21 (21) . Eight weeks later, animals received B6 or BALB/c heart grafts together with 1 mg anti-CD8 i.p. (22) . Transplants were monitored daily by palpation in a blinded fashion. Undetectable heart impulses for two consecutive days was considered rejection. Statistical analysis was performed using the Student t test. The prevalence and severity of CAV were quantified by a morphometric approach (23 
RT-PCR and qRT-PCR
RNAwas isolated from cells and tissues using the RNeasy Mini Kit (Qiagen, Valencia, CA). First-strand cDNA was prepared from 5 mg DNAse-treated RNA using oligo(dT) primers and the Superscript First Strand Synthesis System (Invitrogen, Carlsbad, CA). One-fourth of the total cDNA was used as template for each PCR reaction. + DCs, first-strand cDNA was prepared from 1 mg DNAsetreated RNA, as detailed above. PCR amplifications were done in triplicate in a 25-ml final volume containing 13 SYBR green PCR buffer (Stratagene), 5.5 mM MgCl 2 , 200 nM each primer, 0.6 U platinum Taq DNA polymerase, and 2 ml cDNA. PCR amplifications were carried out in an Mx3000P QPCR System (Stratagene), with an initial denaturing step at 94˚C for 10 min, followed by 40 cycles of 94˚C for 30 s, 52˚C for 30 s, and 72˚C for 1 min. Expression levels were normalized to hypoxanthine phosphoribosyltransferase. The primers for eGFP were 59-AGCACGACTTCTTCAAGTCCG and 59-GTGTCGCCCTCGAACTTCAC-39. For hypoxanthine phosphoribosyltransferase, we used 59-TGAAGAGCTACTGTAATGATCAGTCAA and 59-AGCAAGCTTGCAACCTTAACCA.
ELISPOT assays
These assays were performed according to published techniques (25) . The Journal of Immunology
Results
Expression of a single-donor MHCII gene prevents rejection of fully allogeneic heart transplants As depicted in Fig. 1 , CBA (H-2 k ) mice were reconstituted with syngeneic BMCs that were previously transduced with a vector containing the allogenic MHCII A b gene (MHCII IAb.RV) or a control GFP gene (GFP.RV) ( Fig. 2A) . Hereafter, these mice are referred to as IAb-CBA and GFP-CBA mice, respectively. These animals were monitored for repopulation of blood cells and showed normal levels by 8 wk after bone marrow (BM) infusion compared with naive CBA animals (data not shown). -transduced CBA mice (n = 15) received B6 (n = 11) or third-party BALB/c hearts (n = 4) that were monitored for survival. Controls were CBA mice (n = 7) engineered with the GFP.RV vector and transplanted with B6 hearts. Representative histology of two long-term accepted B6 hearts from IAb-CBA mice (C, D) and a B6 transplant rejected by a control GFP-CBA mouse (E) (Verhoeff elastic stain, original magnifications 3200 (C), 3320 (D), and 3640 (E) at POD 177, 175, and 23, respectively). CAV lesions were quantified as detailed in Materials and Methods. , and IL-4 (C, F) ELISPOT assays were performed on splenocytes from naive CBA (white bars) and IAb-CBA (black bars) mice. Assays were done 8 wk after BM transplantation, prior to heart transplantation (n = 3) and 10 d after transplantation of B6 heart grafts (n = 3). Stimulator cells were irradiated splenocytes from BALB/c or B6 mice. MEM: control medium. Results are mean 6 SD.
(MST, 18 6 7 d; n = 15; data not shown). Likewise, GFP-CBA recipients acutely rejected B6 heart transplants (MST, 29 6 6 d; (Fig. 2B) . Thus, the transfer of a single donor MHCII IA b gene in recipient BMCs was sufficient to prevent the acute rejection of IA b+ grafts that were fully allogeneic with regard to MHC class I and minor Ags to the host genotype. T cell tolerance induced by MHCII gene therapy seemed to be donor-specific, because thirdparty allografts were promptly rejected.
MHCII gene transfer markedly reduces chronic rejection characterized by CAV
Chronic rejection characterized by CAV is the main cause of heart graft failure after the first year of transplantation in patients. In this study, we investigated whether long-term surviving B6 hearts from IAb-CBA recipients exhibited CAV lesions. The onset and severity of CAV were analyzed using our standard histomorphometric test to evaluate intimal thickening and subsequent luminal occlusion on numerous graft vessels (23) . The B6 heart grafts being rejected by control GFP-CBA mice (Fig. 2B ) displayed severe CAV associated with fibrosis and intimal occlusion that was detectable as early as 14-28 d posttransplantation (Fig. 2E) . In contrast, the B6 hearts collected from IAb-CBA mice had no signs of chronic rejection and displayed normal vessel architecture for as long as 177 d after transplantation (Fig. 2C, 2D) . Therefore, in addition to preventing acute allograft rejection, expression of donor-type MHCII gene in hematopoietic cells of graft recipients also thwarted chronic rejection of heart allografts.
Expression of donor MHCII in graft recipients modulates antidonor alloresponses
Acute rejection of allotransplants is dependent upon the activation/ expansion of proinflammatory T cells secreting type 1 cytokines (IL-2 and IFN-g) (26) . Conversely, T cells secreting type 2 cytokines (IL-4 and -10) have been implicated in the prolongation of allograft survival (27) , presumably by suppressing inflammatory T cell immunity (28) . These observations prompted us to examine whether the IA b gene transfer in CBA mice had altered their ability to mount a T cell-mediated alloresponse to B6 allogeneic cells (Fig. 3) . The frequency and specificity of activated T cells producing type 1 (IL-2 and IFN-g) or type 2 (IL-4) cytokines were measured in control CBA and IAb-CBA mice. To test this, T cells from control CBA and IAb-CBA mice were collected prior to and 10 d after placement of a B6 cardiac allotransplant. These cells were then cultured for 24-48 h in the presence of donor B6 or third-party BALB/c irradiated stimulators and the numbers of types 1 and 2 cytokine-producing T cells were assessed using an ELISPOT assay. A similar frequency of IL-2 producers (∼120 spots/million T cells) was observed for CBA and IAb-CBA T cells responding to third-party BALB/c stimulators, irrespective of the presence of B6 allografts (Fig. 3A,  3D) . A comparable trend developed in anti-BALB/c, IFN-g responses of CBA and IAb-CBA mice (Fig. 3B, 3E, top) . Thus, expression of IA b in IAb-CBA mice did not affect the anti-third party ) (29) . We next measured the inflammatory (type 1) alloresponse of CBA and IAb-CBA mice to B6 stimulators. As seen in Fig. 3A and 3B, these mice developed similar Th1 responses (∼280 spots/million T cells) prior to transplantation, suggesting that the primary anti-MHCII IA b response was intact in IAb-CBA mice. In contrast, the type 1 inflammatory alloresponse was abrogated in the IAb-CBA mice transplanted with a B6 heart compared with the control allotransplanted CBA recipients (Fig. 3D, 3E ). In turn, high frequencies of activated donorspecific T cells secreting type 2 cytokine T cells were found in allotransplanted IAb-CBA mice (Fig. 3F) . Therefore, the acceptance of IAb + B6 transplants in IAb-CBA mice is associated with a shifting from a type 1 proinflammatory antidonor T cell response toward an alloresponse dominated by T cells secreting type 2 cytokines.
Transferred IA b is expressed in lymphoid tissues and in BM-derived DCs
Eight weeks after transfusion of transduced BMCs, the IAb-CBA mice received a B6 heart under anti-CD8 therapy (Fig. 1) . The presence of IA b transcripts was detected in PBMCs from 100% of animals 2 wk after BMC injection, whereas 77% (14/18) were positive at the time of heart transplantation ( Fig. 4B) . The IA b signal faded out over time in all IA b -treated animals to become undetectable in PBMCs by 18 wk posttransduction (Fig. 4B) . A similar pattern of GFP expression was observed when the control GFP.RV vector was used for transduction. In addition, PBLs from control GFP-CBA mice were RT-PCR negative for IA b transcripts (Fig. 4A) . Expression of IA b was further analyzed in lymphoid tissues from CBA-IAb mice that were collected at the time of allograft rejection (2/11 mice) or at postoperative days (PODs) 150-177 in six long-term tolerant animals (Fig. 4B) .
To investigate IA b surface expression in transduced BMCs, we examined cells collected 48 h after ex vivo transduction. Surprisingly, IAb.RV-transduced BMCs were negative for surface IA b (Fig. 5A) , whereas 10-15% of cells stained with specific Abs for endogenous IA k (data not shown). To ascertain whether the absence of surface IA b was due to poor transduction or to cell type-specific constraints, IA b expression was further studied in DCs derived from transduced BM, because DCs are key players in thymocyte negative selection (2) . Bulk cultures of DCs derived from control GFP transduction were fluorescent, as were immature DCs (iDCs) and mDCs that differentiated from those cultures (Fig. 5B) . Unexpectedly, iDCs and mDCs obtained from superinfected IAb-GFP BMCs were negative for IAb-GFP and positive for endogenous IA k (Fig. 5C, panels 1-3 ). This suggests a defective IA b gene transcription in DCs and/or an intracellular cleavage of the ectopic IA b a-and b-chains. The former hypothesis was tested by comparing GFP transcript and protein levels in IAb-GFP-transduced DCs and control fibroblast cells (L cells). Results presented in Fig. 5C , panels 4-6, indicated that transcription of IAb-GFP in DCs was not compromised. Finally, monensin was used to block protein transport in A20 monocytic, MHCII + cells transduced with IAb-GFP.RV. Results suggested that cytosolic IAb-GFP fusion protein was shortlived (Fig. 5C, panels 7 and 8 ).
Tregs from tolerant IAb gene recipients transfer transplantation tolerance to naive animals
Our data on indefinite survival of fully allogeneic B6 heart grafts implanted in IAb-CBA recipients (Fig. 2B) lend support to the notion of complete inactivation of type 1 inflammatory alloresponses to B6 graft major and minor Ags, a phenomenon tentatively attributed to Tregs (30) . Therefore, we examined whether acceptance of B6 allogeneic hearts could be achieved in naive CBA mice, recipients of purified Tregs from long-term tolerant IAb-CBA mice. The in vitro suppressive function of IAb-CBA Tregs was first assessed on two tolerant mice at 177 and 178 d post-heart transplantation by a standard Treg suppression assay (31) . Results indicated that CD4 + CD25 + Tregs from IAb-CBA and naive CBA mice were poorly and equally suppressive of CD4 2 and CD4 + CD25 + T cells were purified from naive CBA mice, CBA mice infused with a donor-specific transfusion (CBA+DST), or long-term tolerant IAb-CBA mice treated with DST (IAb-CBA+DST). Each T cell subset was injected separately into naive CBA mice that also received a dose of anti-CD8 mAb and B6 heart grafts on the following day. The effects of adoptive transfer of CD4 + CD25
2 (white columns) and CD4 + CD25 + (gray columns) T cells on graft survival were monitored. Each point represents survival data from a single mouse. p Survival time (days; mean 6 SD). Treg and CD4 + CD25 2 Foxp3 2 effectors subsets were isolated (purity .90%) from DST-treated IAb-CBA recipients as well as from naive CBA mice injected or not with DST ( Fig. 1) . These cell populations were injected separately into naive CBA mice together with one dose of anti-CD8. Treated animals were challenged the following day with B6 allografts, according to the protocol detailed in Fig. 1 . Transfer of CD25 2 or CD25 + T cell subsets, isolated from untreated CBA mice, did not result in statistically significant improvements in graft survival over that of nontransferred controls (Fig. 6, left panel 
Discussion
The present study demonstrated that mice expressing a single donortype MHCII molecule at the time of transplantation of fully allogeneic heart grafts become tolerant to the whole donor/recipient antigenic disparity, a phenomenon referred to as linked or infectious tolerance (33) . The tolerogenic effects of MHCII gene therapy is not unique to the murine heart transplantation model; we previously reported that MHCII gene transfer induced tolerance to MHCII transgene-matched renal allografts in large animals (16) . Transfer of fibroblasts expressing donor MHC class I and MHCII prolonged cardiac allograft survival in mice (34) , suggesting an equal role for MHCI and MHCII genes in regulating immune responses. However, in contrast to our gene-therapy approach, these experiments did not induce transplantation tolerance. In addition, retroviral transfer of MHCI K b gene in BMCs also failed to induce spreading tolerance to K b+ grafts coexpressing third-party Ags (35) . Thus, our findings strongly suggest that induction of spreading tolerance is a property of MHCII molecules. Although transduction rates were not as high as those for CBA BMCs, extended prolongation of graft survival was also observed in BALB/c mice receiving IA b genes and B6 transplants (75 6 6 d; n = 10). This approach also established that linked tolerance was preferentially carried out by Tregs (Fig. 6 ). These points imply that the immune regulatory function of MHCII genes, which has been the cornerstone of their discovery (36) , resides, in part, in their unique ability to generate Tregs.
The long-term surviving heart transplants (.170 d) presented no sign of chronic rejection, the major cause of late graft loss in clinical transplantation (Fig. 2) (37) . Prevention of CAV development has been reported in other models using heavy conditioning with costimulatory blockade, cytolytic drugs, and donor BM infusions (38) . Remarkably, our study showed that transduction of recipient BMCs with a single donor MHCII gene can achieve tolerance to fully allogeneic heart transplants, a result showing that activation of donor-specific Tregs can be sufficient to prevent CAV.
B6 heart transplants survived indefinitely in IA transplants because the latter provide IA b determinants via the direct or indirect pathways for secondary stimulation of GT Tregs and suppression of the antigraft responses. Tolerance to autografts tissues would proceed along the same mechanism involving, this time, native CBA Tregs. Data from autoimmune models have stressed the pivotal role played by MHCII-derived peptides in the reversal of defective Treg functions. For instance, the injection of NOD mice with self-IEb peptide led to Treg activation (45) , whereas binding of IE-derived peptides on IA heterodimers prevented collagen-induced arthritis (46) . The specificity of naturally occurring Tregs for self-MHCII determinants is consistent with results from studies that showed Treg thymic precursors differentiating in the medulla (3), a compartment that is known to selectively display MHCII peptide/MHCII complexes (47) . Such bias of Treg specificity for MHCII determinants may explain how MHCII genes control the effector as well as the regulatory phases of T lymphocyte responses.
